Biopharma PEG Scientific

Biopharma PEG Scientific is a privately held, revenue-generating supplier and manufacturer of PEG-based chemical reagents and linkers. Founded in 2012 and headquartered in Watertown, Massachusetts, USA, the company provides essential components for advanced therapeutic modalities like Antibody-Drug Conjugates (ADCs), PROTACs, and lipid nanoparticles (LNPs). Its business model is primarily service and platform-based, supplying high-purity, functionalized PEGs that are critical for drug development pipelines globally. The company operates with a global distribution network and emphasizes stringent quality control under a GMP-capable framework.

Advanced polymer chemistry platform for the synthesis, purification, and functionalization of high-purity polyethylene glycol (PEG) derivatives and linkers. Capabilities include monodisperse and polydisperse PEG production, a wide array of functional end-groups for bioconjugation (e.g., amine, azide, DBCO, maleimide), and scale-up from mg to 100+ kg under GMP standards, supported by orthogonal analytical QC (NMR, HPLC, MALDI-TOF MS).

Biopharma PEG operates in a competitive market with several established global players specializing in PEG derivatives and bioconjugation reagents, such as Creative PEGWorks, JenKem Technology, NOF America, and Iris Biotech. Differentiation is achieved through product breadth (4000+ items), scale (up to 100kg), GMP capability, and custom synthesis services.